KOL Insight

Non-Small Cell Lung Cancer KOL Interview – NH, US

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Key Questions in Immuno-Oncology

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

Leukemia KOL Insight and Pulse Survey Bundle

The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.

September 8, 2017

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

2015 Cancer Drug Pricing Surveys

$799.00

We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.

August 10, 2015

Diabetic Nephropathy, Diabetes, and Obesity KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits (including off-label) and projections for key marketed brands and late-phase pipeline therapies in diabetic nephropathy, along with information on these drugs and their competitors in the broader diabetes and obesity indications. Key assets highlighted include Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus (and other oral GLP-1 agonists), Mounjaro, Farxiga/AZD9977, Farxiga/zibotentan, and weekly insulins. The KOL also gives insight into reimbursement of Ozempic’s obesity formulation, Wegovy, in obese diabetics.

August 19, 2022

Chronic Heart Failure KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are omecamtiv mecarbil, Zynquista, Invokana, Kerendia, Furoscix, and Revascor.

Chronic Heart Failure KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are Furoscix, Invokana, Kerendia, omecamtiv mecarbil, Revascor, and Zynquista.

Chronic Heart Failure KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are Invokana, Zynquista, and omecamtiv mecarbil.

Chronic Heart Failure KOL Interview – Germany

This interview with a Germany-based key opinion leader (KOL) provides insights into patient segmentation, as well as prescribing trends for key marketed brands and late-phase pipeline therapies for chronic heart failure (CHF). Marketed brands discussed include Entresto, Farxiga, Jardiance, Corlanor, and Verquvo, while pipeline therapies highlighted are omecamtiv mecarbil, Zynquista, Invokana, Kerendia, Furoscix, and Revascor.

Pulmonary Hypertension KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Letairis, Opsumit, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

Pulmonary Hypertension KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

Pulmonary Hypertension KOL Interview – France

This interview with a France-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, Ventavis, Veletri, Flolan, Revatio, Letairis, INOpulse, and sotatercept.

Pulmonary Hypertension KOL Interview – Germany

This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.

Breast Cancer KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Tecentriq, and enobosarm.

July 29, 2022

Breast Cancer KOL Interview – US, Northeast

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Cosela, and enobosarm.

July 18, 2022

Breast Cancer KOL Interview – US, Midwest

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Cosela, and enobosarm.

July 18, 2022

Colorectal Cancer KOL Interview – UK

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

May 23, 2022

Colorectal Cancer KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

May 23, 2022

Melanoma KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

February 25, 2022

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.

April 21, 2022

Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.

Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.

Acute Myeloid Leukemia (AML) KOL Interview – UK

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

Acute Myeloid Leukemia (AML) KOL Interview – Italy

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.

March 14, 2022

Acute Myeloid Leukemia (AML) KOL Interview – US, South

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

Prostate Cancer KOL Interview – UK #2

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

Prostate Cancer KOL Interview – UK #1

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

Prostate Cancer KOL Interview – US, Northeast #2

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

Prostate Cancer KOL Interview – US, Northeast #1

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.

Atopic Dermatitis and Psoriasis KOL Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

Atopic Dermatitis and Psoriasis KOL Interview – US, Southeast

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

Atopic Dermatitis and Psoriasis KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Follicular Lymphoma KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.

June 11, 2021

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021